Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Charu Aggarwal
Perelman Center for Advanced Medicine
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
254 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Graz, Austria
- Research Site
Rankweil, Austria
- Research Site
Vienna, Austria
- Research Site
Vienna, Austria
- Research Site
Blumenau, Brazil
- Research Site
Florianópolis, Brazil
- Research Site
Fortaleza, Brazil
- Research Site
Londrina, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
Taubaté, Brazil
- Research Site
Vitória, Brazil
- Research Site
Sofia, Bulgaria
- Research Site
Sofia, Bulgaria
- Research Site
Varna, Bulgaria
- Research Site
Saint John, New Brunswick, Canada
- Research Site
Brampton, Ontario, Canada
- Research Site
Greater Sudbury, Ontario, Canada
- Research Site
Kitchener, Ontario, Canada
- Research Site
Newmarket, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Saint-Jérôme, Quebec, Canada
- Research Site
Saskatoon, Saskatchewan, Canada
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Changsha, China
- Research Site
Changsha, China
- Research Site
Chengdu, China
- Research Site
Chengdu, China
- Research Site
Chongqing, China
- Research Site
Guangzhou, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Dec 2022
- Primary completion
- 1 Nov 2027
- Completion
- 1 Nov 2027
- Last update posted
- 22 Apr 2026
- Registered enrollment
- 1,350
- Registry id
- NCT05687266
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.